The Effect of Velaglucerase Alfa (Vpriv) on Skeletal Development in Pediatric Gaucher Disease

Gaucher Disease Type 1 Clinical Trial

Official title:
The Effect of Velaglucerase Alfa (Vpriv) on Skeletal Development in Pediatric Gaucher Disease

Status Withdrawn

Clinical Trial Summary

The purpose of this trial is to study the effect of Velaglucerase Alfa on skeletal bone development of children with Type 1 or Type 3 Gaucher Disease. In addition, the natural history and neurological status of children with Type 3 Gaucher Disease will be studied.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02528617
Study type	Interventional
Source	Baylor Research Institute
Contact
Status	Withdrawn
Phase	Phase 4
Start date	July 2015
Completion date	October 2017

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT02583672` - Role of Oxidative Stress and Inflammation in Type 1 Gaucher Disease (GD1)	Phase 2
Recruiting	`NCT04055831` - Immune Biomarkers Related to Bone Pathology in Patients With Type 1 Gaucher Disease
Active, not recruiting	`NCT02843035` - Venglustat in Combination With Cerezyme in Adult Patients With Gaucher Disease Type 3 With Venglustat Monotherapy Extension	Phase 2
Completed	`NCT02067247` - Comparison of BMD Measurement by DEXA to BeamMed Speed-of-Sound Measurement at Forearm in Patients With Gaucher Disease	N/A
Completed	`NCT00319046` - Clinical Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Miglustat in Patients With Stable Type 1 Gaucher Disease	Phase 3
Completed	`NCT06050967` - A Second-generation AI Based Therapeutic Regimen in Patients With Gaucher Disease Treated With Enzyme Replacement Therapy.	Phase 2